Literature DB >> 30855757

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Reply.

Peter Schmid1, Stephen Y Chui2, Leisha A Emens3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30855757     DOI： 10.1056/NEJMc1900150

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  18 in total

1.  Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis.

Authors:  Fabio Conforti; Laura Pala; Vincenzo Bagnardi; Giuseppe Viale; Tommaso De Pas; Eleonora Pagan; Elisabetta Pennacchioli; Emilia Cocorocchio; Pier Francesco Ferrucci; Filippo De Marinis; Richard D Gelber; Aron Goldhirsch
Journal:  J Natl Cancer Inst       Date:  2019-08-01       Impact factor: 13.506

2.  Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapse.

Authors:  Oliver Hoffmann; Sebastian Wormland; Ann-Kathrin Bittner; Monika Collenburg; Peter A Horn; Rainer Kimmig; Sabine Kasimir-Bauer; Vera Rebmann
Journal:  J Cancer Res Clin Oncol       Date:  2022-04-02       Impact factor: 4.553

3.  Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components.

Authors:  Huang-Chun Lien; Yi-Hsuang Lee; I-Chun Chen; Ching-Hung Lin; Tom Wei-Wu Chen; Yueh-Tong Lu; Yen-Shen Lu
Journal:  Virchows Arch       Date:  2020-10-21       Impact factor: 4.064

4.  CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells.

Authors:  Sushil Kumar; Zexian Zeng; Archis Bagati; Rong En Tay; Lionel A Sanz; Stella R Hartono; Yoshinaga Ito; Fieda Abderazzaq; Elodie Hatchi; Peng Jiang; Adam N R Cartwright; Olamide Olawoyin; Nathan D Mathewson; Jason W Pyrdol; Mamie Z Li; John G Doench; Matthew A Booker; Michael Y Tolstorukov; Stephen J Elledge; Frédéric Chédin; X Shirley Liu; Kai W Wucherpfennig
Journal:  Cancer Discov       Date:  2021-03-11       Impact factor: 39.397

5.  Inhibition of stromal biglycan promotes normalization of the tumor microenvironment and enhances chemotherapeutic efficacy.

Authors:  Li Cong; Nako Maishi; Dorcas A Annan; Marian F Young; Hirofumi Morimoto; Masahiro Morimoto; Jin-Min Nam; Yasuhiro Hida; Kyoko Hida
Journal:  Breast Cancer Res       Date:  2021-05-10       Impact factor: 6.466

6.  Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors.

Authors:  François Bertucci; Laurys Boudin; Pascal Finetti; Christophe Van Berckelaer; Peter Van Dam; Luc Dirix; Patrice Viens; Anthony Gonçalves; Naoto T Ueno; Steven Van Laere; Daniel Birnbaum; Emilie Mamessier
Journal:  Oncoimmunology       Date:  2021-05-23       Impact factor: 8.110

7.  A prospective phase II clinical trial identifying the optimal regimen for carboplatin plus standard backbone of anthracycline and taxane-based chemotherapy in triple negative breast cancer.

Authors:  Caroline Hamm; Bre-Anne Fifield; Amin Kay; Swati Kulkarni; Rasna Gupta; John Mathews; Rosa-Maria Ferraiuolo; Huda Al-Wahsh; Emily Mailloux; Abdulkadir Hussein; Lisa A Porter
Journal:  Med Oncol       Date:  2022-02-01       Impact factor: 3.064

Review 8.  microRNAs Orchestrate Pathophysiology of Breast Cancer Brain Metastasis: Advances in Therapy.

Authors:  Ranjana K Kanchan; Jawed A Siddiqui; Sidharth Mahapatra; Surinder K Batra; Mohd W Nasser
Journal:  Mol Cancer       Date:  2020-02-15       Impact factor: 27.401

Review 9.  Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma.

Authors:  Teresa Magnes; Sandro Wagner; Dominik Kiem; Lukas Weiss; Gabriel Rinnerthaler; Richard Greil; Thomas Melchardt
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

10.  BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer.

Authors:  William Jacot; Evelyne Lopez-Crapez; Caroline Mollevi; Florence Boissière-Michot; Joelle Simony-Lafontaine; Alexandre Ho-Pun-Cheung; Elodie Chartron; Charles Theillet; Antoinette Lemoine; Raphael Saffroy; Pierre-Jean Lamy; Séverine Guiu
Journal:  Cancers (Basel)       Date:  2020-03-30       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.